InsidersTradesSigma
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Browse the detailed record of transactions filed by Hillan Kenneth J., Director. Officer active across 2 companies, notably 23andMe Holding Co.. Cumulatively, 12 disclosures have been logged. Breakdown: 0 buy · 1 sell. Total volume traded: €32k. History available since 9 February 2022. The latest transaction was filed on 12 June 2025 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
12 of 12 declarations
Hillan Kenneth J. is Chief Therapeutics Officer at 23andMe Holding Co. and Director at Sangamo Therapeutics, INC. He has 12 filings in total, and across the 12 sampled recent filings between 2022-02-11 and 2025-06-16, sales total EUR 31960 and the most common transaction nature is Attribution.